Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...

More than 450 fans of fashion icon Lilly Pulitzer attended events in Palm Beach, Palm Beach Gardens and West Palm Beach ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a ...

Eli Lilly will acquire Verve for roughly $1 billion Verve is developing a one-time gene-editing treatment for heart disease The company's lead drug, Verve-102, targets a gene linked to high ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Eli Lilly One of the biggest healthcare companies in the world, Eli Lilly is known for its weight loss drugs. The company has a market cap of $729 billion and the stock is exchanging hands for $769.

Eli Lilly is no longer just a pharmaceutical giant—it’s becoming a platform company that’s reshaping the very structure of global healthcare.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will summarize the bulls’ thesis on LLY.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral obesity drug. Click for my LLY update.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth initiatives. Click for my LLY update.

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.